Actinium Pharmaceuticals (ATNM) Shares Outstanding (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Shares Outstanding (Entity) of $31.4 million for Q1 2026, up 0.57% year-over-year from $31.2 million in Q1 2025, and up 0.57% quarter-over-quarter from $31.2 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Shares Outstanding (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Shares Outstanding (Entity) for 17 consecutive years, with $31.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 0.57% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at $31.4 million (up 0.57% YoY), while the FY2025 annual figure was $31.2 million, changed 0.0% from the prior year.
- Shares Outstanding (Entity) advanced to $31.4 million in Q1 2026 per ATNM's latest filing, from $31.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $31.4 million in Q1 2026 and bottomed at $22.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $28.5 million across 5 years, with a median of $29.4 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 17.92% — and 2025, when it changed 0.0%.
- Actinium Pharmaceuticals' Shares Outstanding (Entity) stood at $25.7 million in 2022, then advanced by 7.63% to $27.6 million in 2023, then advanced by 12.89% to $31.2 million in 2024, then changed by 0.0% to $31.2 million in 2025, then increased by 0.57% to $31.4 million in 2026.
- Business Quant data shows ATNM's Shares Outstanding (Entity) at $31.4 million in Q1 2026, $31.2 million in Q4 2025, and $31.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 31.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.40 Mn |
| Mar 31, 2026 | 31.24 Mn |
| Dec 31, 2025 | 31.20 Mn |
| Sep 30, 2025 | 31.20 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 31.20 Mn |
| Dec 31, 2024 | 30.07 Mn |
| Sep 30, 2024 | 31.07 Mn |
| Jun 30, 2024 | 30.10 Mn |
| Mar 31, 2024 | 27.89 Mn |
| Dec 31, 2023 | 26.60 Mn |
| Sep 30, 2023 | 27.06 Mn |
| Jun 30, 2023 | 26.22 Mn |
| Mar 31, 2023 | 25.70 Mn |
| Dec 31, 2022 | 24.14 Mn |
| Sep 30, 2022 | 25.16 Mn |
| Jun 30, 2022 | 23.73 Mn |
| Mar 31, 2022 | 22.14 Mn |
| Dec 31, 2021 | 20.57 Mn |
| Sep 30, 2021 | 21.54 Mn |